Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DEK Expression is Controlled by E2F and Deregulated in Diverse Tumor Type

12 May 2006

Abstract excerpt

Deregulation of the retinoblastoma (pRB) tumor suppressor pathway associated with aberrant activity of E2F transcription factors is frequently observed in human cancer. Microarray based analyses have revealed a large number of potential downstream mediators of the tumor suppressing activity of pRB, including DEK, a fusion partner of CAN found in a subset of acute myeloid leukaemia (AML) patients carrying a (6; 9)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Retinoids in leukemia and cellular processes
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16721057
DOI: 10.4161/cc.5.11.2801

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DEK Expression is Controlled by E2F and Deregulated in Diverse Tumor TypePMID 16721057Read ↗

The DEK oncoprotein binds to highly and ubiquitously expressed genes with a dual role in their transcriptional regulationSemantic proximity Read ↗

DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML)Semantic proximity Read ↗

Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation In vitro and In vivoSemantic proximity Read ↗

The human DEK oncogene regulates DNA damage response signaling and repairSemantic proximity Read ↗

KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastomaSemantic proximity Read ↗

DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.Semantic proximity Read ↗

Negative Regulation of the RelA/p65 Transactivation Function by the Product of the DEK Proto-oncogeneSemantic proximity Read ↗

C/EBPα and DEK coordinately regulate myeloid differentiationSemantic proximity Read ↗

The chromatin remodeler DEK promotes proliferation of mammary epithelium and is associated with H3K27me3 epigenetic modificationsSemantic proximity Read ↗

Characterization of E2F8, a novel E2F-like cell-cycle regulated repressor of E2F-activated transcriptionSemantic proximity Read ↗

DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancerSemantic proximity Read ↗

Putting the Oncogenic and Tumor Suppressive Activities of E2F into ContextSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.